The association of non-motor symptoms with motorsymptoms in parkinson’s disease

Aim: Idiopathic Parkinson’s disease (IPD) is the second most common progressive neurodegenerative disorder and well known with typical motor impairment. Besides motor symptoms, non-motor symptoms (NMS) occur very frequently among patients with IPD. This study aims to assess the presence of non-motor symptoms with the severity of motor symptoms.Materials and Methods: Alaaddin Keykubat University Training and Research Hospital’s database has been screened for identifying patients with IPD from 2015-2019. The patients’ motor symptom, NMS, and Hoehn & Yahr stage (H&Y stage) were assessed with the Movement Disorder Society - Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).Results: A total of 50 IPD patients were analyzed. Analysis by NMS part of MDS-UPDRS (Part I) showed that NMS was present in 99.7% of patients. NMS part score was positively correlated with H&Y stages and total motor scores of MDS-UPDRS (part II-III). The most common symptoms were pain (84%), daytime sleepiness (78%), and urinary problems (76%). Significantly, there was an association between motor impairment, H&Y, and the following NMS items; hallucinations/psychosis, depressed mood, daytime sleepiness, urinary problems, constipation, light-headedness on standing, and fatigue (p

PDF

___

1. Gibb W, Lees A. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality 1967. Neurology 1998;50:318.
3. Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord 2011;17:717-23.
4. Chaudhuri KR, Tolosa E, Schapira AH, Poewe W. Nonmotor symptoms of Parkinson's disease: OUP Oxford; 2014.
5. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S, et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Movement Disorders 2010;25:704-9.
6. 6. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR, Group NV. The impact of nonmotor symptoms on health-related quality of life of patients with Parkinson's disease. Movement Disorders 2011;26:399-406.
7. Chaudhuri KR, Sauerbier A, Rojo J, Sethi K, et al. The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. Parkinsonism Relat Disord 2015;21:287-91.
8. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Movement disorders: Mov Disord 2001;16:507-10.
9. Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007;22:1623-9.
10. Kadastik-Eerme L, Muldmaa M, Lilles S, Rosenthal M, Taba N, Taba P. Nonmotor features in Parkinson’s disease: what are the most important associated factors? Parkinson’s Disease 2016;2016.
11. Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, et al. Movement disorder society criteria for clinically established early Parkinson's disease. Movement Disorders 2018;33:1643-6.
12. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Societysponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129- 70.
13. Rodriguez-Blazquez C, Forjaz MJ, Martinez-Martin P. Rating Scales for Movement Disorders With Sleep Disturbances: A Narrative Review Front Neurol 2018;9:435.
14. Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson's progression markers initiative cohort. Mov Disord Clin Pract 2018;5:47-53.
15. Gallagher DA, Schapira A. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45.
16. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45.
17. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-12.
18. Hermanowicz N, Jones SA, Hauser RA. Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey. Neuropsychiatr Dis Treat 2019;15:2205-12.
19. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-9.
20. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-44.
21. Kasten M, Kertelge L, Tadic V, Brüggemann N, Schmidt A, van der Vegt J, et al. Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson's disease. Mov Disord 2012;27:754-9.
22. de Mattos DC, Meziat Filho NA, Pedron CA, Vasconcellos LF, et al. Pain Characteristics and Their Relationship With Motor Dysfunction in Individuals With Parkinson Disease—A Cross-Sectional Study. Pain Practice 2019;19:732-9.
23. Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O. Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008;23:1361-9.
24. Defazio G, Antonini A, Tinazzi M, Gigante A, Pietracupa S, et al. Relationship between pain and motor and non-motor symptoms in Parkinson's disease. Eur J Neurol 2017;24:974-980.
25. Lajoie A, Lafontaine A, Kaminska M. The spectrum of sleep disorders in Parkinson’s disease: A review. Chest 2021;159:818-27.
26. Schrempf W, Brandt MD, Storch A, Reichmann H. Sleep disorders in Parkinson's disease. J Parkinsons Dis 2014;4:211-21.
27. McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson's disease: prevalence, aetiology and management. Parkinsonism Relat Disord 2017;35:8-16.
28. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Movement disorders. Mov Disord 2009;24:2175-86.
29. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59.
30. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993;34:465-70.
31. Yulug B, Ozan E, Gonul AS, Kilic E. Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Res Bull 2009;78:267-9.
32. Caglayan AB, Beker MC, Caglayan B, et al. Acute and Post-acute Neuromodulation Induces Stroke Recovery by Promoting Survival Signaling, Neurogenesis, and Pyramidal Tract Plasticity. Front Cell Neurosci 2019;13:144.
33. Cankaya S, Cankaya B, Kilic U, et al. The therapeutic role of minocycline in Parkinson’s disease. Drugs Context 2019;8:212553.
34. Yulug B. Neuroprotective treatment strategies for poststroke mood disorders: A minireview on atypical neuroleptic drugs and selective serotonin re-uptake inhibitors. Brain Res Bull 2009;80:95-9.